Jerome Alan Grant
CIK 1723537 · Chief Executive Officer · last filed 2026-03-02
Jerome Alan Grant is a Chief Executive Officer who has filed 35 SEC Form 4 insider transactions across 1 company since 2017. The most recent filing, for UTI, was dated Jun 29, 2026. Across all open-market trades the lifetime net is −$5.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $8.7M across reported positions. 4 Form 144 notices of planned sales are also on file; the latest, for UTI on Jun 29, 2026, lists the filer as an officer and director.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
UTI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PHOENIX, AZ 85032
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| UTI | Chief Executive Officer | 430,215 | $20.21 | $8.69M | -$5.61M | 31 | 2026-03-02 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-29 | UTI | Notice (144) Officer, Director · Planned Jun 29, 2026 No sale on file |
−94,500 | -$3.91M | EDGAR |
| 2026-03-02 | UTI | Sell (S) | −60,040 | -$2.10M | EDGAR |
| 2026-02-27 | UTI | Notice (144) Officer, Director · Planned Feb 27, 2026 Sold: Form 4 filed Mar 2, 2026 |
−60,040 | -$2.10M | EDGAR |
| 2025-12-19 | UTI | Tax (F) | −9,276 | -$241.7K | EDGAR |
| 2025-12-12 | UTI | Mixed | −39,487 | -$2.74M | EDGAR |
| 2025-12-10 | UTI | Grant (A) | +194,394 | $0 | EDGAR |
| 2025-05-14 | UTI | Sell (S) | −56,492 | -$1.91M | EDGAR |
| 2025-05-12 | UTI | Notice (144) Officer, Director · Planned May 12, 2025 Sold: Form 4 filed May 14, 2025 |
−56,492 | -$1.91M | EDGAR |
| 2024-12-17 | UTI | Mixed | +32,322 | -$587.2K | EDGAR |
| 2024-12-16 | UTI | Grant (A) | +67,295 | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).